BioAsia 2014: GSK's emerging markets balance and why Seretide generics are no big deal
This article was originally published in Scrip
Volatility, forex fluctuations and China issues notwithstanding, GlaxoSmithKline maintains that the emerging markets are a good place to be and that the arrival of generic versions of Seretide in these markets is little cause for concern given its tiered pricing approach.
You may also be interested in...
Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.
The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.